image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 2.65
-5.69 %
$ 4.76 M
Market Cap
-0.25
P/E
1. INTRINSIC VALUE

Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.[ Read More ]

The intrinsic value of one STSS stock under the base case scenario is HIDDEN Compared to the current market price of 2.65 USD, Sharps Technology, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart STSS

image
FINANCIALS
0 REVENUE
0.00%
-10.1 M OPERATING INCOME
-15.88%
-9.84 M NET INCOME
-112.12%
-8.51 M OPERATING CASH FLOW
-32.24%
-698 K INVESTING CASH FLOW
77.60%
8.03 M FINANCING CASH FLOW
-34.37%
0 REVENUE
0.00%
-2.02 M OPERATING INCOME
-4.90%
-2.1 M NET INCOME
-114.00%
-1.64 M OPERATING CASH FLOW
13.23%
-1.02 M INVESTING CASH FLOW
-35541.76%
2.97 M FINANCING CASH FLOW
750392.93%
Balance Sheet Decomposition Sharps Technology, Inc.
image
Current Assets 4.84 M
Cash & Short-Term Investments 3.01 M
Receivables 0
Other Current Assets 1.83 M
Non-Current Assets 6.95 M
Long-Term Investments 0
PP&E 6.82 M
Other Non-Current Assets 129 K
Current Liabilities 3.69 M
Accounts Payable 794 K
Short-Term Debt 0
Other Current Liabilities 2.9 M
Non-Current Liabilities 162 K
Long-Term Debt 0
Other Non-Current Liabilities 162 K
EFFICIENCY
Earnings Waterfall Sharps Technology, Inc.
image
Revenue 0
Cost Of Revenue 891 K
Gross Profit -891 K
Operating Expenses 10.1 M
Operating Income -10.1 M
Other Expenses -285 K
Net Income -9.84 M
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-124.04% ROE
-124.04%
-83.48% ROA
-83.48%
-127.24% ROIC
-127.24%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Sharps Technology, Inc.
image
Net Income -9.84 M
Depreciation & Amortization 882 K
Capital Expenditures -698 K
Stock-Based Compensation 963 K
Change in Working Capital -1.12 M
Others 545 K
Free Cash Flow -9.21 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Sharps Technology, Inc.
image
STSS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Sharps Technology, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
239 K USD 7
6-9 MONTHS
33.4 K USD 3
9-12 MONTHS
Date Value Insider Amount Avg Price
6 months ago
Apr 26, 2024
Bought 21.4 K USD
Ruemler Timothy James
Director
+ 75000
0.285 USD
6 months ago
Apr 26, 2024
Bought 28.5 K USD
Christiansen Soren Bo
Director
+ 100000
0.285 USD
6 months ago
Apr 26, 2024
Bought 21.4 K USD
Monroe Jason L.
Director
+ 75000
0.285 USD
6 months ago
Apr 26, 2024
Bought 42.7 K USD
Hayes Robert Michael
Chief Executive Officer
+ 150000
0.285 USD
6 months ago
Apr 26, 2024
Bought 71.2 K USD
DANNER PAUL K
Director
+ 250000
0.285 USD
6 months ago
Apr 26, 2024
Bought 21.4 K USD
Simpson Brenda Baird
Director
+ 75000
0.285 USD
6 months ago
Apr 26, 2024
Bought 28.5 K USD
Crescenzo Andrew R.
Chief Financial Officer
+ 100000
0.285 USD
8 months ago
Feb 20, 2024
Bought 3.4 K USD
Hayes Robert Michael
Chief Executive Officer
+ 10000
0.34 USD
9 months ago
Feb 06, 2024
Bought 2.9 K USD
Hayes Robert Michael
Chief Executive Officer
+ 10000
0.29 USD
9 months ago
Feb 02, 2024
Bought 2.8 K USD
Hayes Robert Michael
Chief Executive Officer
+ 8000
0.35 USD
9 months ago
Jan 31, 2024
Bought 390 USD
Hayes Robert Michael
Chief Executive Officer
+ 1000
0.39 USD
9 months ago
Jan 31, 2024
Bought 456 USD
Hayes Robert Michael
Chief Executive Officer
+ 1200
0.38 USD
10 months ago
Jan 03, 2024
Bought 2 K USD
Ruemler Timothy James
Director
+ 5000
0.4 USD
10 months ago
Jan 02, 2024
Bought 1.79 K USD
Ruemler Timothy James
Director
+ 4466
0.4 USD
10 months ago
Dec 28, 2023
Bought 1.48 K USD
Crescenzo Andrew R.
Chief Financial Officer
+ 3500
0.4216 USD
10 months ago
Dec 22, 2023
Bought 4.02 K USD
Ruemler Timothy James
Director
+ 10000
0.4016 USD
11 months ago
Nov 22, 2023
Bought 4.5 K USD
Ruemler Timothy James
Director
+ 10000
0.45 USD
11 months ago
Nov 22, 2023
Bought 4.5 K USD
Ruemler Timothy James
Director
+ 10000
0.45 USD
11 months ago
Nov 20, 2023
Bought 2.07 K USD
Ruemler Timothy James
Director
+ 5000
0.4149 USD
1 year ago
Nov 17, 2023
Bought 2.05 K USD
Ruemler Timothy James
Director
+ 5000
0.41 USD
1 year ago
Nov 17, 2023
Bought 2.05 K USD
Ruemler Timothy James
Director
+ 5000
0.4099 USD
1 year ago
Nov 16, 2023
Bought 415 USD
Ruemler Timothy James
director, 10 percent owner:
+ 1000
0.415 USD
1 year ago
Nov 16, 2023
Bought 988 USD
Ruemler Timothy James
director, 10 percent owner:
+ 2500
0.395 USD
1 year ago
Nov 15, 2023
Bought 1.02 K USD
Ruemler Timothy James
director, 10 percent owner:
+ 2500
0.41 USD
1 year ago
Apr 14, 2023
Bought 5.12 K USD
Hayes Robert Michael
Chief Executive Officer
+ 4000
1.28 USD
1 year ago
Mar 15, 2023
Bought 822 USD
Hayes Robert Michael
Chief Executive Officer
+ 600
1.37 USD
1 year ago
Mar 15, 2023
Bought 2.03 K USD
Hayes Robert Michael
Chief Executive Officer
+ 1500
1.35 USD
1 year ago
Mar 14, 2023
Bought 1.34 K USD
Hayes Robert Michael
Chief Executive Officer
+ 1000
1.34 USD
1 year ago
Mar 13, 2023
Bought 1.34 K USD
Hayes Robert Michael
Chief Executive Officer
+ 1000
1.34 USD
1 year ago
Mar 13, 2023
Bought 1.39 K USD
Hayes Robert Michael
Chief Executive Officer
+ 1000
1.39 USD
1 year ago
Feb 22, 2023
Bought 670 USD
Hayes Robert Michael
Chief Executive Officer
+ 500
1.34 USD
1 year ago
Feb 21, 2023
Bought 1.37 K USD
Hayes Robert Michael
Chief Executive Officer
+ 1000
1.37 USD
1 year ago
Feb 21, 2023
Bought 405 USD
Hayes Robert Michael
Chief Executive Officer
+ 300
1.35 USD
1 year ago
Feb 21, 2023
Bought 268 USD
Hayes Robert Michael
Chief Executive Officer
+ 200
1.34 USD
1 year ago
Feb 17, 2023
Bought 1.34 K USD
Hayes Robert Michael
Chief Executive Officer
+ 1000
1.34 USD
1 year ago
Feb 17, 2023
Bought 695 USD
Hayes Robert Michael
Chief Executive Officer
+ 500
1.39 USD
1 year ago
Jan 25, 2023
Bought 0 USD
Simpson Brenda Baird
Director
+ 90000
0 USD
1 year ago
Jan 25, 2023
Bought 0 USD
Ruemler Timothy James
Director
+ 90000
0 USD
1 year ago
Jan 25, 2023
Bought 0 USD
Monroe Jason L.
Director
+ 90000
0 USD
1 year ago
Jan 25, 2023
Bought 0 USD
Hayes Robert Michael
Chief Executive Officer
+ 330000
0 USD
1 year ago
Jan 25, 2023
Bought 0 USD
DANNER PAUL K
Director
+ 90000
0 USD
1 year ago
Jan 25, 2023
Bought 0 USD
Crescenzo Andrew R.
Chief Financial Officer
+ 25000
0 USD
1 year ago
Jan 25, 2023
Bought 0 USD
Christiansen Soren Bo
Director
+ 135000
0 USD
1 year ago
Jan 25, 2023
Bought 0 USD
Blackman Alan R.
Director
+ 100000
0 USD
2 years ago
Sep 02, 2022
Bought 2.7 K USD
Hayes Robert Michael
Chief Executive Officer
+ 2000
1.35 USD
2 years ago
Aug 30, 2022
Bought 110 USD
Hayes Robert Michael
Chief Executive Officer
+ 82
1.34 USD
2 years ago
Aug 26, 2022
Bought 1.41 K USD
Hayes Robert Michael
Chief Executive Officer
+ 1000
1.41 USD
2 years ago
Aug 22, 2022
Bought 1.34 K USD
Hayes Robert Michael
Chief Executive Officer
+ 1000
1.34 USD
2 years ago
Aug 04, 2022
Bought 1.19 K USD
Hayes Robert Michael
Chief Executive Officer
+ 1000
1.19 USD
2 years ago
Jul 29, 2022
Bought 1 K USD
Hayes Robert Michael
Chief Executive Officer
+ 1000
1 USD
2 years ago
Jul 14, 2022
Bought 202 USD
Hayes Robert Michael
Chief Executive Officer
+ 200
1.01 USD
2 years ago
May 20, 2022
Bought 1.21 K USD
Hayes Robert Michael
Chief Executive Officer
+ 1000
1.21 USD
2 years ago
May 09, 2022
Bought 140 K USD
Ruemler Timothy James
director:
+ 112000
1.25 USD
2 years ago
May 06, 2022
Bought 828 USD
Crescenzo Andrew R.
Chief Financial Officer
+ 637
1.3 USD
2 years ago
May 04, 2022
Bought 1.38 K USD
Hayes Robert Michael
Chief Executive Officer
+ 1000
1.38 USD
2 years ago
May 03, 2022
Bought 0 USD
DANNER PAUL K
director:
+ 10000
0 USD
2 years ago
May 03, 2022
Bought 0 USD
Christiansen Soren Bo
Co-Chairman
+ 15000
0 USD
2 years ago
May 03, 2022
Bought 0 USD
Simpson Brenda Baird
director:
+ 10000
0 USD
2 years ago
May 03, 2022
Bought 0 USD
Monroe Jason L.
director:
+ 10000
0 USD
2 years ago
May 03, 2022
Bought 0 USD
Berler Barry Boris
CTO and Inventor
+ 50000
0 USD
2 years ago
May 03, 2022
Bought 0 USD
Hayes Robert Michael
Chief Executive Officer
+ 70000
0 USD
2 years ago
May 03, 2022
Bought 0 USD
Crescenzo Andrew R.
Chief Financial Officer
+ 15000
0 USD
2 years ago
May 02, 2022
Bought 10.6 K USD
Ruemler Timothy James
director:
+ 8800
1.21 USD
2 years ago
Apr 28, 2022
Bought 12.5 K USD
Blackman Alan R.
CIO and COO
+ 10000
1.25 USD
2 years ago
Apr 27, 2022
Bought 1.44 K USD
Hayes Robert Michael
Chief Executive Officer
+ 1000
1.44 USD
2 years ago
Apr 27, 2022
Bought 12.5 K USD
Blackman Alan R.
CIO and COO
+ 10000
1.25 USD
2 years ago
Apr 25, 2022
Bought 6.85 K USD
Blackman Alan R.
CIO and COO
+ 5000
1.37 USD
2 years ago
Apr 22, 2022
Bought 7.6 K USD
Blackman Alan R.
CIO and COO
+ 5000
1.52 USD
2 years ago
Apr 19, 2022
Bought 2.28 K USD
Hayes Robert Michael
Chief Executive Officer
+ 1000
2.28 USD
2 years ago
Apr 20, 2022
Bought 13.6 K USD
Crescenzo Andrew R.
Chief Financial Officer
+ 6000
2.26 USD
2 years ago
Apr 14, 2022
Bought 125 K USD
Ruemler Timothy James
director:
+ 29400
4.25 USD
2 years ago
Apr 14, 2022
Bought 11.5 K USD
Hayes Robert Michael
Chief Executive Officer
+ 5000
2.3 USD
2 years ago
Apr 14, 2022
Bought 17 K USD
Blackman Alan R.
CIO and COO
+ 4000
4.25 USD
7. News
Sharps Technology, Inc. Announces Stockholders' Approval of Reverse Stock Split Ratio and Effective Date NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc.  (NASDAQ: “STSS” and “STSSW”) ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it will effect a one-for-22 reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on October 15, 2024 at 11:59 PM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Sharps has requested that its Common Stock begin trading on October 16, 2024, on a post-reverse split basis on the Nasdaq under the existing symbol "STSS". globenewswire.com - 1 month ago
Sharps Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on October 7, 2024 NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is reminding shareholders to vote their proxy in favor of the Company's proposal before the shareholder meeting scheduled to be held on October 7, 2024 at 10:00 a.m. Eastern Time. globenewswire.com - 1 month ago
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.5 Million Bridge Financing for Sharps Technology, Inc. (NASDAQ:STSS) NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Bridge Financing for Sharps Technology, Inc. (NASDAQ:STSS). About Sharps Technology, Inc. Sharps Technology, Inc., a medical device company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States. accesswire.com - 1 month ago
Sharps Technology, Inc. Closes $3.5 Million Bridge Financing NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced secured bridge loan financing (the “Bridge Financing”) of approximately $3.5 million. globenewswire.com - 1 month ago
Sharps Technology, Inc. Announces $3.5 Million Bridge Financing NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into definitive agreements with institutional investors for a secured bridge loan financing (the “Bridge Financing”) of approximately $3.5 million. globenewswire.com - 1 month ago
Sharps Technology Announces Continued Listing on Nasdaq Pending Results of an Upcoming Special Shareholders' Meeting NEW YORK, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: STSS and STSSW) (“Sharps Technology” or the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, announced today that the Company has secured approval from The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) to maintain its listing, subject to conditions outlined below. globenewswire.com - 2 months ago
Sharps Technology CEO Urges Shareholders to Vote in Support of the Three Proposals by the July 12 Voting Deadline Robert Hayes issues a letter to shareholders asking their voting approval on three proposals vital to the Company's continued growth. globenewswire.com - 4 months ago
Nasdaq Surges Over 100 Points; Sharps Technology Shares Spike Higher U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Friday. benzinga.com - 4 months ago
What's Going On With Nano-Cap Medical Device-Focused Sharps Technology On Friday? Shares of Sharps Technology Inc STSS are trading higher on Friday, with a heavy session volume of 15.17 million. benzinga.com - 4 months ago
Sharps Technology Receives Purchase Orders for 1 Million SecureGard Syringes for 2024 Delivery Swiss-based provider of cosmetic, dental, and ophthalmic injectable therapies issues purchase orders for 1mL SecureGard ultra-low waste, smart safety syringes globenewswire.com - 4 months ago
Sharps Technology Ships First Orders for Securegard Disposable Smart Safety Syringes to Strategic Distribution Partner in Colombia Orders for Sharps Securegard 1mL and 3mL syringes are on the water, introducing a line of competitively priced, low waste, smart safety syringes to the Colombian Healthcare System and the Latin American Market Orders for Sharps Securegard 1mL and 3mL syringes are on the water, introducing a line of competitively priced, low waste, smart safety syringes to the Colombian Healthcare System and the Latin American Market globenewswire.com - 5 months ago
Join Sharps Technology's Exclusive Live Investor Webinar and Q&A Session on June 18 NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is pleased to invite investors to a webinar on June 18, 2024, at 4:15 p.m. ET. globenewswire.com - 5 months ago
8. Profile Summary

Sharps Technology, Inc. STSS

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 4.76 M
Dividend Yield 0.00%
Description Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.
Contact 105 Maxess Road, Melville, NY, 11747 https://sharpstechnology.com
IPO Date April 14, 2022
Employees 57
Officers Mr. Robert M. Hayes Chief Executive Officer & Director Mr. Ben Scheu Senior Director of Sales Dr. Steven Hertz M.D. Chief Medical Officer